Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235. [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of a single day of dosing with GSK1614235 in adults with Type 2 diabetes; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GSK1614235

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED